Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the ...

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A ...

The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...

A retrospective study found an association between elevated ALC and CAR+ T-cell counts and development of neurologic events in patients with r/r MM.

The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Age-related changes in blood stem cells are linked to decreased platelet factor 4, marking a critical finding for treating ...

As our hairs go gray and our muscles weaken with age, our immune system also changes. In particular, the stem cells that ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) for sonrotoclax, a ...

As the company continues its optimal dosing investigations, additional infusions have been given to the second and third ...